Cogent Biosciences Unveils CGT1145 with >100-Fold JAK2 Selectivity, IND Filing Set for 2026
COGT•Cogent Biosciences showcased preclinical data for CGT1145, its JAK2 V617F mutant-selective inhibitor demonstrating over 100-fold selectivity versus wild-type JAK2 and JAK1/3 isoforms with high oral bioavailability and low clearance across species. The company remains on track to file an IND for CGT1145 in 2026, targeting molecular remission in MPN patients.
1. EHA Poster Presentation
Cogent Biosciences presented preclinical data on CGT1145 at the 2026 European Hematology Association Congress in Stockholm, highlighting its next-generation profile against the JAK2 V617F mutation.
2. CGT1145 Preclinical Profile
CGT1145 demonstrated over 100-fold selectivity for the V617F mutant versus wild-type JAK2 and JAK1/3 isoforms, combined with high oral bioavailability and low clearance across multiple species, indicating strong potential for molecular remission with reduced off-target effects.
3. IND Filing Plan
Cogent is advancing CGT1145 toward an Investigational New Drug submission slated for 2026, marking a key regulatory milestone in its development pathway for BCR-ABL-negative myeloproliferative neoplasms.
